Arena BioWorks was a privately funded, forâÂÂprofit biomedical research institute in Kendall Square, Cambridge, Massachusetts. Launched in January,à2024, it sought to shorten the path from biological insight to therapeutic development by combining basic research and company creation under one roof. It closed in November 2025.
The origins of Arena BioWorks go back to earlyà2020, when cofounder StuartàSchreiber and a group called âÂÂScientists to Stop COVIDâÂÂ19â coordinated efforts to accelerate vaccine and therapeutic development during the SARSâÂÂCoVâÂÂ2 pandemic, inspiring the concept of applying âÂÂwarpâÂÂspeedâ strategies to other diseases. Following more than two years of planning, the institute operated in stealth mode beginning midâÂÂ2023 at 399àBinneyàStreet with approximately 50 scientists before its public unveiling on Januaryà12,à2024.
Arena BioWorks is governed by a management committee comprising StuartàSchreiber (CEO), SteveàPagliuca (executive chair), and TomàCahill (managing director of Newpath Partners). The institute was capitalized with $500àmillion in private funding from investors including Pagliuca, MichaelàDell, MichaelàChambers, JimàBreyer, and ElisabethàDeLuca. Investors receive up to 30â¯percent of profits from spinâÂÂout companies, with remaining proceeds allocated to scientist compensation, operations, and an endowment for future research.
The institute is headquartered at 399ÃÂ BinneyÃÂ Street in KendallÃÂ Square, near research organizations such as the Broad Institute, Whitehead Institute, Koch Institute, and McGovern Institute for Brain Research.
Arena BioWorks employs a staffâÂÂscientist model that decouples research from academic training, offering permanent positions rather than relying on graduate students or postdoctoral fellows. The institute integrates discovery with inâÂÂhouse company formation, aiming to streamline translation of basic research into therapeutic candidates.
The core scientific leadership includes J.â¯Keith Joung, MD,â¯PhD, an innovator in CRISPR technology who joined from Massachusetts General Hospital as lead translator.
Arena BioWorks pursues a broad, diseaseâÂÂagnostic strategy, prioritizing brain health, oncology, immunology, and aging based on genetic and mechanistic insights. The instituteâÂÂs platform technologies include smallâÂÂmolecule and protein therapeutic discovery, chemoproteomics, molecular glues, covalent drug design, highâÂÂthroughput screening, protein and antibody engineering, gene and epigenetic editing, cell and gene therapies, biomanufacturing, and data science.
Commentators have likened ArenaàBioWorks to the âÂÂBellàLabs of Biotech,â citing its forâÂÂprofit model and expansive funding as an experimental approach to translational research. Critics have raised concerns that lucrative compensation packages may create a âÂÂbrain drainâ from academic institutions, potentially undermining the training and mentorship of future scientists. Others, including MITâÂÂs RobertàLanger, have argued that nonprofit and forâÂÂprofit research entities can coexist, each contributing to advances in human health.
The Broad Institute has signaled interest in exploring collaborative research opportunities with ArenaàBioWorks, recognizing potential synergies between nonprofit and forâÂÂprofit science communities in Kendall Square.